Literature DB >> 28939681

Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.

Rui Yang1, Lee H Chen1, Landon J Hansen1, Austin B Carpenter1, Casey J Moure1, Heng Liu1, Christopher J Pirozzi1, Bill H Diplas1, Matthew S Waitkus1, Paula K Greer1, Huishan Zhu1, Roger E McLendon1, Darell D Bigner1, Yiping He2, Hai Yan2.   

Abstract

Inactivating mutations in the transcriptional repression factor Capicua (CIC) occur in approximately 50% of human oligodendrogliomas, but mechanistic links to pathogenesis are unclear. To address this question, we generated Cic-deficient mice and human oligodendroglioma cell models. Genetic deficiency in mice resulted in a partially penetrant embryonic or perinatal lethal phenotype, with the production of an aberrant proliferative neural population in surviving animals. In vitro cultured neural stem cells derived from Cic conditional knockout mice bypassed an EGF requirement for proliferation and displayed a defect in their potential for oligodendrocyte differentiation. Cic is known to participate in gene suppression that can be relieved by EGFR signal, but we found that cic also activated expression of a broad range of EGFR-independent genes. In an orthotopic mouse model of glioma, we found that Cic loss potentiated the formation and reduced the latency in tumor development. Collectively, our results define an important role for Cic in regulating neural cell proliferation and lineage specification, and suggest mechanistic explanations for how CIC mutations may impact the pathogenesis and therapeutic targeting of oligodendroglioma. Cancer Res; 77(22); 6097-108. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28939681      PMCID: PMC5690824          DOI: 10.1158/0008-5472.CAN-17-1018

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Molecular genetic evidence for subtypes of oligoastrocytomas.

Authors:  D Maintz; K Fiedler; J Koopmann; B Rollbrocker; S Nechev; D Lenartz; A P Stangl; D N Louis; J Schramm; O D Wiestler; A von Deimling
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

3.  A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling.

Authors:  Sergio Astigarraga; Rona Grossman; Julieta Díaz-Delfín; Carme Caelles; Ze'ev Paroush; Gerardo Jiménez
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

4.  Capicua DNA-binding sites are general response elements for RTK signaling in Drosophila.

Authors:  Leiore Ajuria; Claudia Nieva; Clint Winkler; Dennis Kuo; Núria Samper; María José Andreu; Aharon Helman; Sergio González-Crespo; Ze'ev Paroush; Albert J Courey; Gerardo Jiménez
Journal:  Development       Date:  2011-01-26       Impact factor: 6.868

5.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

6.  ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.

Authors:  Yung C Lam; Aaron B Bowman; Paymaan Jafar-Nejad; Janghoo Lim; Ronald Richman; John D Fryer; Eric D Hyun; Lisa A Duvick; Harry T Orr; Juan Botas; Huda Y Zoghbi
Journal:  Cell       Date:  2006-12-29       Impact factor: 41.582

7.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

8.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

9.  CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.

Authors:  Vincent Gleize; Agusti Alentorn; Léa Connen de Kérillis; Marianne Labussière; Aravidan A Nadaradjane; Emeline Mundwiller; Chris Ottolenghi; Stephanie Mangesius; Amithys Rahimian; François Ducray; Karima Mokhtari; Chiara Villa; Marc Sanson
Journal:  Ann Neurol       Date:  2015-07-27       Impact factor: 10.422

10.  Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination.

Authors:  Ben Emery; Dritan Agalliu; John D Cahoy; Trent A Watkins; Jason C Dugas; Sara B Mulinyawe; Adilijan Ibrahim; Keith L Ligon; David H Rowitch; Ben A Barres
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

View more
  14 in total

Review 1.  The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer.

Authors:  Lucía Simón-Carrasco; Gerardo Jiménez; Mariano Barbacid; Matthias Drosten
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

Review 2.  Molecular Pathogenesis of Low-Grade Glioma.

Authors:  Devin Bready; Dimitris G Placantonakis
Journal:  Neurosurg Clin N Am       Date:  2019-01       Impact factor: 2.509

3.  Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.

Authors:  Qiumin Tan; Lorenzo Brunetti; Maxime W C Rousseaux; Hsiang-Chih Lu; Ying-Wooi Wan; Jean-Pierre Revelli; Zhandong Liu; Margaret A Goodell; Huda Y Zoghbi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-30       Impact factor: 11.205

4.  CIC is a critical regulator of neuronal differentiation.

Authors:  Inah Hwang; Heng Pan; Jun Yao; Olivier Elemento; Hongwu Zheng; Jihye Paik
Journal:  JCI Insight       Date:  2020-05-07

5.  Rapid Dynamics of Signal-Dependent Transcriptional Repression by Capicua.

Authors:  Shannon E Keenan; Shelby A Blythe; Robert A Marmion; Nareg J-V Djabrayan; Eric F Wieschaus; Stanislav Y Shvartsman
Journal:  Dev Cell       Date:  2020-03-05       Impact factor: 12.270

6.  The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation.

Authors:  Simon Weissmann; Paul A Cloos; Simone Sidoli; Ole N Jensen; Steven Pollard; Kristian Helin
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

7.  Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors.

Authors:  Shiekh Tanveer Ahmad; Alexandra D Rogers; Myra J Chen; Rajiv Dixit; Lata Adnani; Luke S Frankiw; Samuel O Lawn; Michael D Blough; Mana Alshehri; Wei Wu; Marco A Marra; Stephen M Robbins; J Gregory Cairncross; Carol Schuurmans; Jennifer A Chan
Journal:  Nat Commun       Date:  2019-05-01       Impact factor: 14.919

8.  miR-106b promotes proliferation and invasion by targeting Capicua through MAPK signaling in renal carcinoma cancer.

Authors:  Lu-Jie Miao; Shu Yan; Qian-Feng Zhuang; Qing-Yan Mao; Dong Xue; Xiao-Zhou He; Jian-Ping Chen
Journal:  Onco Targets Ther       Date:  2019-05-13       Impact factor: 4.147

Review 9.  Capicua in Human Cancer.

Authors:  Ji Won Kim; Rovingaile Kriska Ponce; Ross A Okimoto
Journal:  Trends Cancer       Date:  2020-09-22

Review 10.  Regulation and function of capicua in mammals.

Authors:  Yoontae Lee
Journal:  Exp Mol Med       Date:  2020-04-01       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.